A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)

Inclusion Criteria

• •Admitted for delivery at the University of Michigan (UM) Labor and Delivery (L\&D) unit or enrolled in the UM postpartum blood pressure monitoring program following a delivery at the UM L\&D unit
• •Determined to be at least 23 and 0/7 weeks of gestation based on a clinically acceptable dating method (can be a single or multifetal gestation with or without the presence of fetal anomalies) at the time of delivery
• •Consents to participation and must understand/read/speak English with the ability to understand and willingness to sign a written informed consent in English
• •Diagnosed with a hypertensive pregnancy by either of the following criteria:
• •* Taking an antihypertensive medication for the diagnosis of chronic or essential hypertension at the time of admission
• •* Hypertension, chronic hypertension, or essential hypertension must be present in the prospective participant's medical record
• •* Antihypertensive" can be any medication taken for the purpose of blood pressure control per the medical record
• •* A documented hypertensive disorder of pregnancy (gestational hypertension, preeclampsia without severe features, preeclampsia with severe features, superimposed preeclampsia, or eclampsia) prior to delivery
• •Eligible participants must report a planned contraceptive method as part of the consent process, to be noted on their consent document.
• •Has two or more blood pressures ≥160/110 Millimeters of mercury (mmHg) at least 60 minutes apart
• •* If an admitted patient does not meet this blood pressure criterion but is otherwise eligible, participants can consent to have a BNP drawn within 12 hours of delivery as an alternative measure of cardiovascular risk (if the brain natriuretic peptide (BNP) is ≥100 Picograms per milliliter (pg/ml), participants are eligible to participate)